We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now . Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is one of the best low-priced pharma stocks on this list.

TheFly reported on June 11 that XERS announced that the USPTO issued a notice of allowance for U.S. Patent Application No. 17/151,405, covering compositions and methods of use related to its Keveyis product. The allowed claims were determined to meet patentability requirements and are expected to advance toward patent issuance after completing standard administrative procedures. Following approval, Xeris plans to submit the patent for inclusion in the FDA's Orange Book listing. If issued and maintained through required filings and fees, the new patent is expected to extend intellectual property protection for Keveyis through 2039.

Simultaneously, on June 11, Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) entered into privately negotiated exchange agreements with holders of its 8.00% Convertible Senior Notes due 2028. Under the agreements, the company plans to retire approximately $23 million in principal amount of notes through a combination of cash payments and common stock issuance. The number of shares issued will depend on the volume-weighted average trading price of XERS common stock during a 21-day averaging period beginning June 11. Based on an assumed average price of $6.71, XERS expects to issue about 4.6 million shares. After completion, approximately $10.5 million of notes will remain outstanding.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is a commercial-stage biopharmaceutical company developing ready-to-use, room-temperature stable therapies for endocrine and neurological disorders.

While we acknowledge the potential of XERS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years

Disclosure: None. Follow Insider Monkey on Google News .